Chinook Therapeutics, Inc. (KDNY)

NASDAQ: KDNY · IEX Real-Time Price · USD
18.05
-0.61 (-3.27%)
At close: Jun 24, 2022 4:00 PM
17.61
-0.44 (-2.44%)
After-hours: Jun 24, 2022 4:41 PM EDT
-3.27%
Market Cap 1.11B
Revenue (ttm) 53.97M
Net Income (ttm) -97.41M
Shares Out 61.61M
EPS (ttm) -1.96
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,223,560
Open 18.97
Previous Close 18.66
Day's Range 17.80 - 19.13
52-Week Range 10.48 - 19.59
Beta n/a
Analysts Buy
Price Target 35.99 (+99.4%)
Earnings Date Aug 11, 2022

About KDNY

Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. Its product candidates also include BION-1301, an anti-APRIL monoclonal antibody is being evaluated in a Phase I/II trial for IgA nephropathy; and CHK-336, an oral small molecule LDHA inhibitor for the t... [Read more...]

Industry Biotechnology
CEO Stephen Isaacs
Employees 138
Stock Exchange NASDAQ
Ticker Symbol KDNY
Full Company Profile

Financial Performance

In 2021, KDNY's revenue was $51.63 million, an increase of 6,142.44% compared to the previous year's $827,000. Losses were -$102.94 million, 26.1% more than in 2020.

Financial Statements

Analyst Forecast

According to 14 analysts, the average rating for KDNY stock is "Buy." The 12-month stock price forecast is 35.99, which is an increase of 99.39% from the latest price.

Price Target
$35.99
(99.39% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Wall Street Analysts See a 94% Upside in Chinook (KDNY): Can the Stock Really Move This High?

The consensus price target hints at a 93.8% upside potential for Chinook (KDNY). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate re...

Recent Price Trend in Chinook (KDNY) is Your Friend, Here's Why

Chinook (KDNY) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shor...

Does Chinook (KDNY) Have the Potential to Rally 110% as Wall Street Analysts Expect?

The mean of analysts' price targets for Chinook (KDNY) points to a 109.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts ...

Chinook Therapeutics Announces Pricing of a $105 Million Public Offering

SEATTLE, May 24, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY) today announced the pricing of its underwritten public offering of 6,428,572 shares of its common stock at a price to ...

Chinook Therapeutics Announces Proposed Public Offering

SEATTLE, May 24, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for ki...

Chinook (KDNY) Upgraded to Buy: What Does It Mean for the Stock?

Chinook (KDNY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Wall Street Analysts Believe Chinook (KDNY) Could Rally 110%: Here's is How to Trade

The average of price targets set by Wall Street analysts indicates a potential upside of 109.9% in Chinook (KDNY). While the effectiveness of this highly sought-after metric is questionable, the positiv...

Chinook Therapeutics Presents Data from Atrasentan Phase 2 AFFINITY IgA Nephropathy (IgAN) Patient Cohort and Evotec ...

SEATTLE, May 20, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for ki...

Chinook's Kidney Disease Candidate Continues To Show Rapid, Sustained Reductions In Biomarkers

Chinook Therapeutics Inc (NASDAQ: KDNY) announced updated interim results from the Phase 1/2 study of BION-1301 in IgA nephropathy (IgAN). IgAN, also known as Berger's disease, is a kidney disease that ...

Chinook Therapeutics Presents Updated Data from BION-1301 Phase 1/2 Trial in Patients with IgA Nephropathy (IgAN) and...

SEATTLE, May 18, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for ki...

Chinook Therapeutics Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

SEATTLE, May 12, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for ki...

Chinook Therapeutics Provides Business Update and Reports First Quarter 2022 Financial Results

SEATTLE, May 12, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for ki...

Chinook Therapeutics Announces Upcoming Data Presentations and Investor Conference Call at the 59th European Renal As...

SEATTLE, May 02, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (NASDAQ: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for ki...

Chinook Therapeutics to Present at the 2022 Bloom Burton & Co. Healthcare Investor Conference

SEATTLE, April 25, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for ...

Chinook Therapeutics Announces Initiation of Phase 1 Healthy Volunteer Trial of CHK-336, a First-in-Class LDHA Inhibi...

SEATTLE, April 12, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (NASDAQ: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for ...

Chinook Therapeutics to Present at the 21st Annual Needham Virtual Healthcare Conference

SEATTLE, April 05, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for ...

Chinook Therapeutics, IgA Nephropathy Foundation and Komodo Health Collaborate to Provide Nephrologists with Support ...

SEATTLE, April 05, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), the IgA Nephropathy Foundation and Komodo Health today announced an outreach initiative leveraging data and technol...

Chinook Therapeutics Announces Appointment of Dr. Mahesh Krishnan to its Board of Directors

SEATTLE, March 21, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (NASDAQ: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for ...

Chinook Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results

SEATTLE, March 17, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for ...

Chinook Therapeutics to Present at Oppenheimer's 32nd Annual Healthcare Conference

SEATTLE, March 08, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (NASDAQ: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for ...

4 Small Drug Stocks That Appear to Be Solid Bets in a Challenging Industry

Some business disruption due to COVID-19 was felt by the Medical-Drugs industry players in 2021. CPRX, KDNY, ASRT and SGTX may prove to be good additions to one's portfolio.

Other symbols: ASRTCPRXSGTX

Chinook Therapeutics Announces Upcoming Presentations at 4th Annual Chronic Kidney Disease Drug Development Summit

SEATTLE, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (NASDAQ: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for k...

Wall Street Analysts Predict a 153% Upside in Chinook (KDNY): Here's What You Should Know

The consensus price target hints at a 152.9% upside potential for Chinook (KDNY). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate r...

Chinook Therapeutics Announces Upcoming Encore Presentations at ISN World Congress of Nephrology 2022

SEATTLE, Feb. 18, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (NASDAQ: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for k...

Chinook Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference

SEATTLE, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (NASDAQ: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for k...